New York City, NY – According to filings with the U.S. Securities and Exchange Commission, Redpin Therapeutics is raising $30,000,000.00 in new funding. Sources indicate as part of senior management President, Elma Hawkins played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Redpin Therapeutics

At Redpin Therapeutics we are a privately held, preclinical stage gene therapy company based in New York City. We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy. Our science is based on the groundbreaking discovery and development of an ultrapotent ion channel-based chemogenetics platform that enables targeted cell activation or inhibition controlled by low doses of the anti-smoking drug varenicline (CHANTIX). We have a worldwide exclusive license from the Howard Hughes Medical Institute for the therapeutic use of this technology, and we are working with urgency to apply it to advance important medicines for patients in desperate need of effective therapies.

To learn more about Redpin Therapeutics, visit http://www.redpinrx.com/

Contact:
Elma Hawkins, President
917-971-9655
https://www.linkedin.com/in/elma-hawkins-74a37a4/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved